Optimal timing of anti-PD-1 antibody combined with chemotherapy administration in patients with NSCLC.
Huo Y, Wang D, Yang S, Xu Y, Qin G, Zhao C, Lei Q, Zhao Q, Liu Y, Guo K, Ouyang S, Sun T, Wang H, Fan F, Han N, Liu H, Chen H, Miao L, Liu L, Duan Y, Lv W, Liu L, Zhang Z, Cang S, Wang L, Zhang Y.
Huo Y, et al. Among authors: sun t.
J Immunother Cancer. 2024 Dec 19;12(12):e009627. doi: 10.1136/jitc-2024-009627.
J Immunother Cancer. 2024.
PMID: 39706602
Free article.